Published in Cancer Weekly, February 7th, 2006
According to recent research published in the British Journal of Cancer, "This phase I trial was designed to determine the safety and maximum tolerated dose (MTD) of tipifamib in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Furthermore, the pharmacokinetics of each of these agents was evaluated."
"Patients were treated with tipifamib b.i.d. on days 1-7 of each 21-day cycle. In addition, gemcitabine was given as a 30-min i.v. infusion on days 1 and 8 and cisplatin as a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.